DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
Torben BiesterJudith NirKerstin RemusAlon FarfelIdo MullerSarah BiesterEran AtlasKlemen DovcNataša BratinaOlga KordonouriTadej BattelinoMoshe PhilipThomas DanneRevital NimriPublished in: Diabetes, obesity & metabolism (2018)
The MD-Logic system was safe and associated with better glycaemic control than SAP therapy for day and night use. The absence of remote monitoring did not lead to safety signals in adapting basal rates nor in administration of automated bolus corrections.